Neurobiological Measures of Schizotypal Personality Disorder: Defining an Inhibitory Endophenotype?

Subjects included 10 men and 11 women (N=21) with schizotypal personality disorder who were tested on the prepulse inhibition, P50 suppression, and antisaccade paradigms. Details of the experimental methods for each of the paradigms have been reported elsewhere (3, 5, 7). Four of the 21 subjects were receiving psychotropic medication, and 11 reported a family history of psychiatric illness. Before entry into the study, all subjects provided written informed consent after receiving an explanation of the study. Subjects received one of two startle paradigms (3). The percentage of prepulse inhibition (30-msec interstimulus interval) was converted to z scores. The mean prepulse inhibition of comparison subjects (z=0.2) minus 1 standard deviation (z=0.8) from a previous report (3) was chosen in determining a deficit cutoff z score of –0.6. We previously reported that subjects with schizotypal personality disorder had deficits in P50 suppression relative to those in normal comparison subjects (5). A cutoff score of 19% P50 suppression was determined on the basis of the mean (64%) for the normal comparison subjects minus one standard deviation (45%) in this study. Cutoff scores were determined for the antisaccade paradigm on the basis of the mean proportion correct (0.84) for the normal comparison subjects minus one standard deviation (0.12) (cutoff score=0.72)(7).

Seven (33%) of the subjects with schizotypal personality disorder scored below the prepulse inhibition cutoff, seven scored below the P50 suppression cutoff, and seven scored below the antisaccade cutoff, while seven (33%) had no deficits on any paradigm (Table 1). Of the seven subjects who had P50 suppression deficits, five (71%) also had antisaccade deficits. Additionally, 81% (N=17) of the subjects with schizotypal personality disorder had concordant scores (both abnormal or both normal) on P50 suppression and antisaccade paradigm performance. The observed frequencies of performance on the P50 suppression and antisaccade paradigms were analyzed to assess the independence of the measures. The null hypothesis was rejected (χ²=6.9, df=1, p<0.01; p<0.02, Fisher’s exact test), suggesting that performance on the P50 suppression and antisaccade paradigms is not independent. Other tests of association (prepulse inhibition and P50 suppression, prepulse inhibition and antisaccade task) were nonsignificant. Demographic and clinical ratings were also similarly assessed, and there were no significant relationships found between gender, family history of psychotic illness, clinical rating, or psychotropic medication use and any of the physiological paradigms.

The distributions of the P50 suppression and prepulse inhibition data were skewed, and the P50 suppression and antisaccade data were not normally distributed. One outlier was identified in the prepulse inhibition data (z=–3.5) and was excluded from the analyses. Spearman’s rank-order correlations revealed a significant correlation between P50 suppression and antisaccade performance (r=0.49, p<0.05, N=20). Correlations between prepulse inhibition and the other measures were nonsignificant.

Individuals diagnosed with schizotypal personality disorder have a high rate of inhibitory deficits (3, 5, 7), consistent with the pattern seen in schizophrenia patients and their relatives. These preliminary results, with liberal cutoff points, suggest that the inhibitory deficits measured by the P50 suppression and antisaccade paradigms are moderately associated and present in a significant subgroup of subjects with schizotypal personality disorder, while the prepulse inhibition paradigm appears to identify a different subgroup of subjects with schizotypal personality disorder. Neurobiological measures, versus clinical characteristics, may provide simpler, empirically derived endophenotypes with discernible patterns of inheritance due to major genetic effects in schizophrenia spectrum illness (11). These results should be replicated in a larger group of subjects with schizotypal personality disorder as well as in normal and schizophrenia subjects. Comparisons between the P50 suppression and prepulse inhibition paradigms in normal human and animal subjects (12–14) are consistent with the idea that these two “gating” measures do not correlate with each other. In contrast, a significant relationship between P50 suppression and antisaccade performance has been reported in schizophrenia patients and their relatives, and a composite P50 suppression/antisaccade paradigm endophenotype has been linked to a marker on chromosome 22q in these families (15).

The convergence, as well as divergence, in performance data on these measures of inhibitory functioning suggests that there may be overlap and independence in the modulatory neural circuitry and genetic architecture of the three tasks. For example, there are commonalities in the neural substrates of P50 suppression and antisaccade performance (e.g., basal ganglia and frontal circuits) and temporal characteristics that may prove important in future neurophysiological and genetic studies.

Presented in part at the 39th annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, Dec. 10–14, 2000. Received April 4, 2001; revision received Oct. 2, 2001; accepted Oct. 10, 2001. From the Department of Psychiatry, University of California, San Diego. Address reprint requests to Dr. Cadenhead, Department of Psychiatry, 0810, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0810; [email protected] (e-mail). Supported in part by NIMH grants MH-01124, MH-18399, MH-51129, and MH-42228; Young Investigator Awards (to Drs. Cadenhead and McDowell) from the National Alliance for Research on Schizophrenia and Depression; and a grant from the Department of Veterans Affairs VISN 22 Mental Illness Research Education and Clinical Center. The authors thank Kathleen Shafer, Colleen Brenner, and Joyce Sprock for their support of this research.